Curasight

"We had a busy quarter, announcing key data for uTREAT in non-small lung cancer as we continue to validate our theranostics approach for improved diagnosis and treatment of certain cancers." Stated Curasight's CEO Ulrich Krasilnikoff. "We also spent time during the quarter planning our updated strategy - which we announced following the end of the period - to accelerate our clinical development in parallel for uTREAT and uTRACE. We believe Curasight's value in the future will be driven by this and our ability to build partnerships to support later stage clinical development and towards commercialization. To execute on our goals, we need to have a stable financial foundation and therefore we launched a rights issue at the start of the new year, providing an opportunity for shareholders to support the further development of the company by injecting more funding into the business."

Q4 (2023-10-01 - 2023-12-31)

• Gross loss amounted to kDKK -5,493 (kDKK -3,792)
• Operating loss amounted to kDKK -7,907 (kDKK -7,066)
• Loss before tax amounted to kDKK -7,892 (kDKK -7,095)
• Loss for the period amounted to kDKK -6,413 (kDKK -6,810)
• Total assets amounted to kDKK 38,742 (kDKK 59,667)
• Equity ratio amounted to 81,0% (96,5%)
• Earnings per share amounted to DKK -0,32 (DKK -0,34)

Q1-Q4 (2023-01-01 - 2023-12-31)

• Gross loss amounted to kDKK -25,729 (kDKK -11,488)
• Operating loss amounted to kDKK -33,214 (kDKK -18,862)
• Loss before tax amounted to kDKK -33,220 (kDKK -19,488)
• Loss for the year amounted to kDKK -26,169 (kDKK -18,349)
• Total assets amounted to kDKK 38,742 (kDKK 59,667)
• Equity ratio amounted to 81,0% (96,5%)
• Earnings per share amounted to DKK -1,32 (DKK -0,92)